Phase II study of two-weekly temozolomide in patients with high-grade gliomas.

Journal Article (Journal Article;Multicenter Study)

Palliative chemotherapy has an increasing role in the management of recurrent high-grade gliomas. Temozolomide is a well-tolerated agent that results in objective responses and stabilisation of disease. Theoretically, temozolomide may be more effective when given in a prolonged schedule rather than the standard 5 days-monthly schedule. This Phase II study examined the efficacy and toxicity of temozolomide when given in a two-weekly schedule. Twenty-five patients received 150 mg/m2 temozolomide daily for seven days alternating with seven days of no treatment. One cycle of temozolomide was a total of two weeks treatment in every 28 days. Of the 25 evaluable patients, there was one complete response (4%), four partial responses (16%) and 10 patients had disease stablisation (40%). The progression free survival at 6 months was 56%. Two-weekly temozolomide was well tolerated with only four episodes of Grade 3 thrombocytopenia. Overall, two-weekly temozolomide is an active and well tolerated schedule, but does not appear to improve on the activity of temozolomide using the standard 5-day schedule.

Full Text

Duke Authors

Cited Authors

  • Wong, S; Rosenthal, MA; Dowling, A; Jennens, R; Woods, A-M; Ashley, D; Cher, L

Published Date

  • January 2006

Published In

Volume / Issue

  • 13 / 1

Start / End Page

  • 18 - 22

PubMed ID

  • 16356721

International Standard Serial Number (ISSN)

  • 0967-5868

Digital Object Identifier (DOI)

  • 10.1016/j.jocn.2004.10.018


  • eng

Conference Location

  • Scotland